

Elos Medtech receives funds for dental surface project from Innovation Fund Denmark

Elos Medtech has in collaboration with researchers at DTU, the Technical University of Denmark, and the iNANO center at Aarhus University started a new surface project to whiten titanium. The Innovation Fund Denmark has invested 10 million DKK into the research project, which will be finalized by 2022.

Treating tooth loss with dental implants is increasing worldwide and this trend is accompanied by an increasing demand towards better aesthetic results. In relation to the latter, the grey color of the titanium metal, typically used for manufacturing dental implants, is an aesthetic challenge. Depending on the thickness of the soft tissue and the location of the dental implant in the patient's mouth, the grey color can be visible through the tissue. Additionally, if recession of the soft tissue or bone loss is experienced, the metal components can be directly exposed. All these factors will have a negatively impact on the aesthetic outcome of the restoration.

Currently, the research team has been able to prepare aesthetic white, stable, titanium surfaces in laboratory setting, thus, indicating the feasibility of achieving the goal of developing a technology for large scale production, allowing for solving the aesthetic challenge.

'We have set an ambitious goal to develop a robust technology to whiten titanium, while complying with the regulatory requirements. Then, the technology can be used commercially', says Ole Zoffmann Andersen, Phd and research manager at Elos Medtech.

'The vision of Elos Medtech is to transform medical technology and advancing quality of life worldwide. A successful development of this new technology will have a great impact on quality of life for patients that are treated with dental implants. When we succeed, it will redefine the definition of aesthetic dentistry and, by that, set a new standard', says Sören Olesen, Business Director Dental Implants at Elos Medtech.

Elos Medtech is one of the leading development and production partners for medical technology products and components in the world, with focus on dental and orthopedic implants and instruments. We operate at facilities in Sweden, Denmark, China and the US. Customers are medical technology companies worldwide.

Elos Medtech employs more than 500 people worldwide and generates revenue that exceeds MSEK 550. Elos Medtech has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list.

Gothenburg, January 28, 2019

Elos Medtech AB (publ)

For further information, contact:

Jan Wahlström, President and CEO, +46 70-212 18 89, jan.wahlstrom@elosmedtech.com
Sören Olesen, Managing Director Elos Medtech Pinol and Business Director Dental Implants, +45 40 41 28 82, soren.olesen@elosmedtech.com

This is the type of information that Elos Medtech AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was issued for publication by the contact persons stated above on January 28, 2019, at 08.00 (CET).

For additional information about surface research at Elos Medtech,
visit elosmedtech.com/author/ole-zoffmann-andersen/

For additional information about the Elos Medtech Group, visit www.elosmedtech.com